Table 4.
Responses (By Tumor Type and Dose Level).
| # Evaluable | CR | PR | SD | PD | ORR* (%) | |
|---|---|---|---|---|---|---|
| All Patients | 67 | 5 | 22 | 32 | 8 | 27/67 (40%) |
| By Tumor Type | ||||||
| Lung | 16 | 1 | 6 | 7 | 2 | 7/16 (44%) |
| Breast | 13 | 3 | 6 | 2 | 2 | 9/13 (69%) |
| Melanoma | 9 | 0 | 1 | 7 | 1 | 1/9 (11%) |
| Head & Neck | 8 | 0 | 3 | 5 | 0 | 3/8 (38%) |
| Bladder | 6 | 1 | 2 | 2 | 1 | 3/6 (50%) |
| Carcinoma of unknown origin | 3 | 0 | 1 | 2 | 0 | 1/3 (33%) |
| Esophageal | 2 | 0 | 0 | 2 | 0 | 0/2 (0%) |
| Cholangiocarcinoma | 2 | 0 | 0 | 2 | 0 | 0/2 (0%) |
| Ampulla of Vater | 1 | 0 | 0 | 1 | 0 | 0/1 (0%) |
| Adrenalcortical carcinoma | 1 | 0 | 0 | 0 | 1 | 0/1 (0%) |
| Stomach | 1 | 0 | 1 | 0 | 0 | 1/1 (100%) |
| Uterine | 1 | 0 | 1 | 0 | 0 | 1/1 (100%) |
| Prostate | 1 | 0 | 1 | 0 | 0 | 1/1 (100%) |
| Myxoid chondrosarcoma | 1 | 0 | 0 | 1 | 0 | 0/1 (0%) |
| Adenoid cystic of lung | 1 | 0 | 0 | 1 | 0 | 0/1 (0%) |
| Cervix | 1 | 0 | 0 | 0 | 1 | 0/1 (0%) |
| By Dose Level | ||||||
| Level 1 | 5 | 0 | 2 | 2 | 1 | 2/5 (40%) |
| Level 2 | 8 | 1 | 1 | 6 | 0 | 2/8(25%) |
| Level 3 | 3 | 0 | 1 | 2 | 0 | 1/3 (33%) |
| Level 4 | 3 | 0 | 1 | 2 | 0 | 1/3 (33%) |
| Level 5 | 12 | 2 | 4 | 5 | 1 | 6/12 (50%) |
| Level 6 | 5 | 1 | 1 | 2 | 1 | 2/5 (40%) |
| Level 7 | 9 | 1 | 5 | 2 | 1 | 6/9 (67%) |
| Level 7B | 14 | 0 | 3 | 8 | 3 | 3/14 (21%) |
| Level 8 | 8 | 0 | 4 | 3 | 1 | 4/8 (50%) |
Abbreviation: ORR-Overall response rate